Physician profile
Supriya Rao
NPI 1205098886
$27,708.60
in general payments reported to CMS, 2019-2025
25 companies · $8,894 in 2025
The $8,894 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.64 · 2020: $35.84 · 2021: $62.33 · 2022: $142 · 2023: $490 · 2024: $18K · 2025: $8,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Food and Beverage: $3,199 · Honoraria: $1,206 · Education: $21.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,000.00 |
| Food and Beverage | $3,198.79 |
| Honoraria | $1,206.00 |
| Education | $21.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17,228.11 | 2019-2025 | |
| Lilly USA, LLC | $6,129.43 | 2025 | Zepbound |
| Celltrion USA INC. | $1,354.72 | 2024-2025 | Zymfentra |
| Abbvie INC. | $593.10 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $462.62 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Gilead Sciences, INC. | $342.86 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $285.71 | 2023-2025 | Entyvio, Gattex |
| Genzyme Corporation | $218.64 | 2024-2025 | |
| Medtronic, INC. | $158.75 | 2023 | Interstim |
| Janssen Biotech, INC. | $112.12 | 2023-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $108.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $91.35 | 2023-2025 | Vowst |
| Regeneron Healthcare Solutions, INC. | $83.24 | 2024-2025 | Dupixent |
| Alnylam Pharmaceuticals INC. | $83.17 | 2025 | Givlaari |
| Boston Scientific Corporation | $78.79 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $74.62 | 2021-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $65.97 | 2022-2025 | |
| Celgene Corporation | $47.89 | 2023-2024 | Zeposia |
| Organon LLC | $43.03 | 2023-2024 | Hadlima |
| Phathom Pharmaceuticals, INC. | $32.86 | 2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $29.05 | 2024 | |
| Ardelyx, INC. | $28.50 | 2025 | Ibsrela |
| Qol Medical, LLC | $24.88 | 2025 | Sucraid |
| Currax Pharmaceuticals LLC | $15.81 | 2025 | Contrave |
| Orphalan INC | $15.06 | 2025 | Cuvrior |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supriya Rao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.